Molly K Steele1, Justin V Remais2, Manoj Gambhir3, John W Glasser4, Andreas Handel5, Umesh D Parashar4, Benjamin A Lopman6. 1. Epidemiology Branch, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, United States; Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322, United States. Electronic address: molly.steele@emory.edu. 2. Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA 94720, United States. 3. Epidemiological Modelling Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne Vic 3004, Australia. 4. Epidemiology Branch, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, United States. 5. Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA 30602, United States. 6. Epidemiology Branch, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, United States; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, United States.
Abstract
BACKGROUND: Noroviruses are the leading cause of acute gastroenteritis and foodborne diarrheal disease in the United States. Norovirus vaccine development has progressed in recent years, but critical questions remain regarding which age groups should be vaccinated to maximize population impact. METHODS: We developed a deterministic, age-structured compartmental model of norovirus transmission and immunity in the U.S. POPULATION: The model was fit to age-specific monthly U.S. hospitalizations between 1996 and 2007. We simulated mass immunization of both pediatric and elderly populations assuming realistic coverages of 90% and 65%, respectively. We considered two mechanism of vaccine action, resulting in lower vaccine efficacy (lVE) between 22% and 43% and higher VE (hVE) of 50%. RESULTS: Pediatric vaccination was predicted to avert 33% (95% CI: 27%, 40%) and 60% (95% CI: 49%, 71%) of norovirus episodes among children under five years for lVE and hVE, respectively. Vaccinating the elderly averted 17% (95% CI: 12%, 20%) and 38% (95% CI: 34%, 42%) of cases in 65+ year olds for lVE and hVE, respectively. At a population level, pediatric vaccination was predicted to avert 18-21 times more cases and twice as many deaths per vaccinee compared to elderly vaccination. CONCLUSIONS: The potential benefits are likely greater for a pediatric program, both via direct protection of vaccinated children and indirect protection of unvaccinated individuals, including adults and the elderly. These findings argue for a clinical development plan that will deliver a vaccine with a safety and efficacy profile suitable for use in children.
BACKGROUND: Noroviruses are the leading cause of acute gastroenteritis and foodborne diarrheal disease in the United States. Norovirus vaccine development has progressed in recent years, but critical questions remain regarding which age groups should be vaccinated to maximize population impact. METHODS: We developed a deterministic, age-structured compartmental model of norovirus transmission and immunity in the U.S. POPULATION: The model was fit to age-specific monthly U.S. hospitalizations between 1996 and 2007. We simulated mass immunization of both pediatric and elderly populations assuming realistic coverages of 90% and 65%, respectively. We considered two mechanism of vaccine action, resulting in lower vaccine efficacy (lVE) between 22% and 43% and higher VE (hVE) of 50%. RESULTS: Pediatric vaccination was predicted to avert 33% (95% CI: 27%, 40%) and 60% (95% CI: 49%, 71%) of norovirus episodes among children under five years for lVE and hVE, respectively. Vaccinating the elderly averted 17% (95% CI: 12%, 20%) and 38% (95% CI: 34%, 42%) of cases in 65+ year olds for lVE and hVE, respectively. At a population level, pediatric vaccination was predicted to avert 18-21 times more cases and twice as many deaths per vaccinee compared to elderly vaccination. CONCLUSIONS: The potential benefits are likely greater for a pediatric program, both via direct protection of vaccinated children and indirect protection of unvaccinated individuals, including adults and the elderly. These findings argue for a clinical development plan that will deliver a vaccine with a safety and efficacy profile suitable for use in children.
Authors: Gemma Phillips; Clarence C Tam; Stefano Conti; Laura C Rodrigues; David Brown; Miren Iturriza-Gomara; Jim Gray; Ben Lopman Journal: Am J Epidemiol Date: 2010-04-01 Impact factor: 4.897
Authors: R G Wyatt; R Dolin; N R Blacklow; H L DuPont; R F Buscho; T S Thornhill; A Z Kapikian; R M Chanock Journal: J Infect Dis Date: 1974-06 Impact factor: 5.226
Authors: Faizel H A Sukhrie; Peter Teunis; Harry Vennema; Cedrick Copra; Matthias F C Thijs Beersma; Jolanda Bogerman; Marion Koopmans Journal: Clin Infect Dis Date: 2012-01-30 Impact factor: 9.079
Authors: Manish M Patel; Marc-Alain Widdowson; Roger I Glass; Kenichiro Akazawa; Jan Vinjé; Umesh D Parashar Journal: Emerg Infect Dis Date: 2008-08 Impact factor: 6.883
Authors: Meghana P Parikh; Simon Vandekar; Christina Moore; Linda Thomas; Nathan Britt; Bhinnata Piya; Laura S Stewart; Einas Batarseh; Lubna Hamdan; Steffany J Cavallo; Ashley M Swing; Katie N Garman; Lisha Constantine-Renna; James Chappell; Daniel C Payne; Jan Vinjé; Aron J Hall; John R Dunn; Natasha Halasa Journal: Clin Infect Dis Date: 2020-12-03 Impact factor: 9.079
Authors: Molly K Steele; Mary E Wikswo; Aron J Hall; Katia Koelle; Andreas Handel; Karen Levy; Lance A Waller; Ben A Lopman Journal: Emerg Infect Dis Date: 2020-08 Impact factor: 6.883
Authors: Frank G Sandmann; Laura Shallcross; Natalie Adams; David J Allen; Pietro G Coen; Annette Jeanes; Zisis Kozlakidis; Lesley Larkin; Fatima Wurie; Julie V Robotham; Mark Jit; Sarah R Deeny Journal: Clin Infect Dis Date: 2018-08-16 Impact factor: 9.079
Authors: T Alex Perkins; Robert C Reiner; Guido España; Quirine A Ten Bosch; Amit Verma; Kelly A Liebman; Valerie A Paz-Soldan; John P Elder; Amy C Morrison; Steven T Stoddard; Uriel Kitron; Gonzalo M Vazquez-Prokopec; Thomas W Scott; David L Smith Journal: PLoS Comput Biol Date: 2019-03-20 Impact factor: 4.475